www.eisai.com website review
Improve your SEO :: free trial!
www.eisai.com is 71% geoptimaliseerd!
SEO Keyword summary for www.eisai.com/news/index2013.html
Keywords are extracted from the main content of your website and are the primary indicator of the words this page could rank for. By frequenty count we expect your focus keyword to be eisai
Focus keyword
Short and long tail
Short Tail Keywords eisai release close |
long Tail Keywords (2 words) 2013 eisai news release contact us japanese contact worldwide japanese |
long Tail Keywords (3 words) japanese contact us worldwide japanese contact release worldwide japanese news release worldwide contact us search us search close search close close |
www.eisai.com On-Page SEO Scan
Descriptive Elements
The <head> element of a www.eisai.com/news/index2013.html page is used to inform the browser and visitors of the page about the general meta information. The head section of the page is where we place the page title, the definition of the HTML version used, the language of in which the page is written. In the head section we can also include JavaScript and CSS (markup) files for the page.
Page title
Title length
news releaseiumlfrac eisai ltd
Meta description
Meta description legth
Meta description SEO
welcome eisai official corporate website eisais news release
Content SEO
Number of Words
Spam detected?
Headings
Heading distribution
Heading normalisation
Heading SEO impact
Emphasis (bold and italic)
Emphasis SEO impact
Images
Number of images
Images dimensions
Image alt descriptions
Images SEO impact
newsindexhtml back top hhc human health care facebook linkedin
Mobile SEO www.eisai.com/news/index2013.html
Mobile rendering
Mobile optimizations
Responsive design detected (mobile css)
No flash detected !
Mobile improvement
Marketing / lead generation for www.eisai.com/news/index2013.html
Social Media
Facebook shares | Facebook likes | ||
Facebook comments | Tweets | ||
Google +1 |
Conversion form
Search form
Analytics
Online presence
SERP Preview
SERP Title
SERP Link
SERP Description
Domain Level SEO
Domain name
13 characters long
Domain name SEO Impact
Path name
new found in path !
news found in path !
Structured data
Publisher Markup
Other Structured data
Website configuration
Correct processing of non-existing pages?
Favicon icon found?
HTML request without WWW redirected correctly?
Robots.txt found?
Sitemap found?
Navigation and internal links
Navigation
Url seperator
Human readable urls
Number of links
Link SEO Impact
aboutsite terms of use
|
accessibility accessibility
|
community_guidelines sns community guidelines
|
company worldwide
corporate governance
about eisai
message from top management
corporate concept
corporate information
business activities
video library
eisai at a glance
corporate executives
japan business sites
eisai the first 80 years
basic approach to corporate governance
corporate governance system
board of directors and committees
related rules
compensation for corporate executives
internal audit
products
production and logistics demand chain systems
|
hhc eisais hhc concept
|
innovation innovation
research and development rd
hhceco the hhc concept ecosystem
open innovation
corporate venture capital
eisais drug discovery research and development sites worldwide
flow of rd drug creation research
latest major rd pipeline
key therapeutic areas
clinical trials
use of digital technology
policies and guidelines
collaboration with partners
|
inquiry contact us
|
ir investors
management policy
ir library
financial data
ir events calendar
stock bond information
ir site map
mediumterm business plan eway future beyond
basic policy for capital strategy
basic policies regarding persons to control the determination of financial and business policies of the company
eisai group disclosure policy
financial reports
shareholder reports
value creation report environmental report human capital report
presentations
financial highlights
fact sheet
ir calendar
stock information
bonds and ratings
analyst coverage
general meeting of shareholders
|
news 2023 release
launch of measurement reagent kit e test tosoh pivka for use with tosoh aia systems in detecting hepatocellular carcinoma diagnosticaid marker pivkadcp in japan
eisai to present new research on halaven eribulin at 36th annual san antonio breast cancer symposium
notification regarding execution of business transfer agreement to transfer business operations at eisai misato plant to bushu pharmaceuticals ltd
notification regarding implementation of voluntary retirement program
eisai product creation systems epcs undergoes transformation with aim of further focusing and strengthening product creation capabilities
eisai submits application for proton pump inhibitor pariet in japan seeking indication expansion for prevention of recurrent gastric or duodenal ulcer caused by lowdose aspirin therapy and approval of new formulation
eisai to receive japan marketing authorization holder license from nobelpharma for antineoplastic agent gliadel 77 mg implant
eisai joins groundbreaking tuberculosis drug accelerator partnership to discover new tuberculosis drugs
a new strategy for 24hour protection from viruses in the home eisai announces launch of new crystal veil fuite bokin 24 wet wipes containing longacting antimicrobial agent etakhelps prevent viruses and bacteria from adhering to household surfaces
eisai makes donation to victims of typhoon haiyan in philippines
eisai enters global agreement with broad institute to develop new drugs for neglected tropical diseases and tuberculosisdrug discovery project for chagas disease awarded ghit fund grant
eisai expands marketing and supply agreement for antiobesity agent lorcaserin to include most countries worldwideaims to establish weight management global standard that includes drug therapy
eisai submits application to expand indication of antialzheimers agent aricept as treatment for dementia with lewy bodies in japan
eisai begins free supply of diethylcarbamazine in line with its global commitment to eliminate lymphatic filariasisfirst shipment to benefit more than 6 million people in 4 endemic countries
eisai to expand antiobesity agent belviq sales force in us
eisai receives european commission approval on use of antiepileptic agent zonegran in pediatric patients
eisai announces launch of anticancer agent halaven in india
eisai presents additional analysis findings on halaven eribulin at european cancer congress 2013
eisai selected for membership of dow jones sustainability asia pacific index an index for socially responsible investment
eisais us research subsidiary h3 biomedicine enters into collaborative agreement with selvita to create novel anticancer agents
eisai announces launch of anticancer agent halaven as companys first product in russia
eisai announces launch of selbelle ukon 27 plus granule 30 mg of highabsorption curcumin for approx 27 times the absorption
eisai enters community development partnership agreement with city of yokohama to promote local dementia support initiatives
eisai receives prequalification from world health organization for lymphatic filariasis medicine diethylcarbamazinesupply from vizag plant india to 24 endemic countries to begin this year
eisai announces launch of higherdose aricept 23 mg tablet for moderatetosevere alzheimers disease in south korearealizes further contribution to patients with dementia in asia region
eisai receives approval to market pariet triple formulation packs rabecure 400 and 800 and rabefine for primary and secondary h pylori eradication respectively in japan
continuation of policy for protection of the companys corporate value and common interests of shareholders shareholder rights plan
eisai receives positive opinion from emas chmp on use of antiepileptic agent zonegran in pediatric patients
notice regarding transfer of shares of eisai subsidiary
eisai to suspend temporarily commercial distribution of antiepileptic drug fycompa in germanycompany will continue to ensure access to the drug for patients in need of fycompa treatment
eisai announces launch of new dry syrup formulation of alzheimers disease treatment aricept in japan
eisai to make new investment in expansion of global packaging facility at hatfield production plant in uk
abbvie and eisai announce humira prefilled syringe 40 mg 08 ml a fully human monoclonal antitnf antibody formulation has received approval for the treatment of moderate to severe ulcerative colitis uc in japanhumira becomes the first and only selfinjectable biologic therapy for the treatment of moderate to severe uc
eisai to launch chocola bb sparkling vitamin kyutto lemon flavorcontains 5 ingredients that help bring out beauty from within reduced calories
eisai confirms therapeutic effects of lenvatinib in patients with melanoma in strategic collaboration with quintiles to develop eisai anticancer compounds
eisai presents new quality of life findings in patients with metastatic breast cancer from halaven eribulin versus capecitabine study at 49th asco annual meeting
notification regarding partial amendment to the articles of incorporation
notification regarding the completion of the disposal of treasury stock through thirdparty allotment in accordance with the introduction of performancerelated stock compensation system
eisai announces launch of antiepileptic agent inovelon tablets 100 mg 200 mg in japan
abbvie and eisai announce humira prefilled syringe has received approval for the treatment of intestinal behets disease in japanhumira is the first biologic approved to treat intestinal behets disease in japan
eisai to present new research on oncology products and pipeline at 49th asco annual meeting
notification regarding the disposal of treasury stock through thirdparty allotment in accordance with the introduction of performancerelated stock compensation system
notification regarding the introduction of a performancerelated stock compensation system in accordance with the revision of the compensation system for the corporate officers of the company
publication in federal register tomorrow moves belviq closer to launch
eisai files for indication expansion of anticancer agent halaven with european medicines agencyseeks earlierline use in treatment of metastatic breast cancer
eisai supports earthquake relief efforts in sichuan china
eisai to establish new parenteral facility in china
eisai receives manufacturing and marketing authorization for vascular embolization device dc bead in japan
eisai announces preclinical research findings suggesting novel inhibitory effect on tumor metastasis for anticancer agent halaven at aacr 104th annual meeting
eisai coestablishes the global health innovative technology fundaims to advance development of new health tech for the developing world
eisai establishes pharma sales subsidiary in moscow ahead of planned direct sales launch in russia
new drug application for pediatric formulation aciphex sprinkle approved by us fda
eisai to launch botulinum toxin type b neuromuscularblocking agent nerbloc intramuscular injection 2500 units in japan
eisai receives manufacturing and marketing authorization for antiepileptic agent inovelon in japan
symbio and eisai announce removal of treakisym injection 100 mg all cases surveillance condition for japan marketing approval
eisai announces launch of bi chocola collagen and bi chocola collagen gele
new indication approved in japan for lyrica capsules
ajinomoto pharmaceuticals and eisai announce japan launch of antiosteoporotic agent oncemonthly formulation actonel 75 mg tablets
eisai announces launch of chocola bb sparkling fibercontaining 5 ingredients that help bring out beauty from withinincludes dietary fiber equivalent to 16 celery stalks
eisais us subsidiary eisai inc to divest us rights for targretin to valeant
helicobacter pylori gastritis approved as additional indication in japan for helicobacter pylori eradication by triple therapy with proton pump inhibitor
eisais taiwan subsidiary eisai taiwan inc to divest tainan plant to taiwanese pharma company bora
eisai announces results of phase study of anticancer agent farletuzumab in patients with relapsed platinumsensitive ovarian cancer
nobelpharma and eisai announce japan launch of antineoplastic agent gliadel 77 mg implant
eisai signs agreement with epizyme and roche molecular systems to develop companion diagnostic
novartis pharma and eisai terminate copromotion agreement for copd therapies
2022 release
2021 release
2020 release
2019 release
2018 release
2017 release
2016 release
2015 release
2014 release
2013 release
2012 release
2011 release
2010 release
2009 release
2008 release
2007 release
|
privacy privacy policy
|
sitemap sitemap
|
sustainability sustainability
message from top management
eisais sustainability
sustainability management
initiatives for improving access to medicines
environment
society
governance
esg data report
thirdparty assessment
system for promoting sustainability
eisais materiality material topics
sustainability advisory board
initiatives for sustainable development goals
member organizations and initiatives that engage in sustainabilityrelated activities
our concept for access to medicines
initiatives for elimination of neglected tropical diseases
initiatives for improving access to medicines for noncommunicable diseases
research development for improving access to medicines
environmental management
climate countermeasure
establishment of a recyclingoriented society
management of chemical substances
biodiversity conservation
respect for human rights
relationship with customers
relationship with our employees
relationship with business partners
relationship with industry associations and patient groups advocacy
relationship with people throughout society
compliance and risk management
global tax policy
information security
targets and results
esg data and independent assurance
gri content index
|
www.eisai.com |
Links to external pages
Outloing links
reg18.smp.ne.jp
www.eisai.co.jp
www.twitter.com
SEO Advice for www.eisai.com
In this section we provide pointers on how you can to optimize your web page so it can be found more easily by search engines and how to make it rank higher by optimizing the content of the page itself. For each of the individual criteria the maximum score is 100%. A score below 70% is considered to be indication that the page is not complying with general SEO standards and should be evaluated and/or fixed. Not every factor is weighted the same and some are not as important as others. Relatively unimportant factors like meta keywords are not included in the overall score.
Item | Factor | Pointers | |
---|---|---|---|
PageTitle | 100% | Far too many sites lack a page title. A page title is the first thing that shows in the search results so always use the title element. | |
Title relevance | 65% | A title should reflect the contents of a site. This site has a 50 % match | |
Title Length | 100% | Limit your title to anywhere between 40 and 70 characters. Your title was 51 characters long | |
Meta Description | 100% | A meta description is the second element that shows in the search results so always use the meta description. | |
Meta description length | 60% | The meta description should be between 145 and 160 characters. This meta description is 85 characters long. | |
Meta description relevance | 90% | Meta Description should reflect the contents of a site. This site has a 50 % match | |
Number of internal links | 30% | Linking to internal pages makes pages easier to find for search engines. Try to keep the number of links on your page roughly below 100. There are 272 internal links on this page. | |
Folder structure | 100% | We found a folder structure in the links on your page. A good folder structure makes a site easier to navigate. We found 12 level 1 folders and 104 folders above or in the first level of navigation. | |
Headings | 100% | Headers should reflect the contents of a site. This site has a 75 % match | |
Links | 12% | Link anchors should to some degree reflect the contents of a site. This site has a 6 % match | |
Image alt tags | 31% | Image alt tags should to some degree reflect the contents of a site. This site has a 11 % match | |
Bold and italic | 100% | Bold and italic tags should reflect the contents of a site to some degree. This site has a 100 % match | |
Html ratio | 75% | Try to keep the html / text ratio as low as possible. More html means longer loading times. Layout should be handled in a serpate css file | |
Image descriptions | 22% | 22.222222222222 % of all images have been described via the "alt" attribute. Describing images with relevant text may lead to better results in the search engines. | |
Page errors | 100% | Pages with no errors display significantly faster on most browsers. We detected 0 errors and warnings | |
WordCount | 20% | An ideal page contains between 400 and 600 words.This page contains 1924 words | |
Server response time | 30% | A slow server slows down a website. This server responds 860.75% slower the average | |
Gzip compression | 30% | This site does not use Gzip compression. Pages may not display as fast as they could | |
Keywords in Domainname | 100% | There are important keywords in your domain name | |
Keywords in domain path | 100% | There are important keywords in the domain path | |
Structured Data | 100% | Structured data makes it easier for search engines to index your website | |
Inline css | 93% | Do not use inline css declarations. Inline css will slow down the rendering of the website. We detected 2 inline style declarations ( <a style="color:green">) with a size of 60 bytes | |
Excessive use of the same words | 100% | There is no indication that there are one or more keywords that are used excessively. | |
Frames or iframes | 20% | The use of (i)frames can lead to problems crawling your page. Wij found 2 frame(s) on your page | |
Flash | 100% | Perfect, we detected no flash objects on your page | |
Css | 100% | Perfect, we did not detect too many CSS files | |
Javascript | 30% | Wij detected too much (4) blocking JavaScript files. Try to combine or defer the loading of JavaScript files | |
Mobile Website | 100% | Perfect, we found a responsive design for mobile users | |
Most important heading | 100% | Perfect, we detected a correct use of the most important (h1) heading! | |
Normalized headings | 100% | Perfect, we found a correct use of normalized headings ! |
How would you like to have SEO advice for all your pages ?? Start your SEO Dashboard and optimize your website!
www.eisai.com images and descriptions
7 images found at www.eisai.com Images can improve the user experience for a website by making a pag visually appealing Images can also add extra keyword relevance to a webpage by using alt tags. Images can also slow down a website. If the width and height for a picture is not specified for a browser know in advance how large the image is. A browser must first load the picture and see before it knows how much space should be on the page. Upon reservation In the meantime, the browser can do little but wait. When the height and width for the plate are given in the HTML code, a browser just continues to build for a page while the images load in the background.
http://www.eisai.com/common/images/header/logo.svg height: height attribute not set width: width attribute not set description: /news/index.html |
|
http://www.eisai.com/common/images/icon_search.png height: height attribute not set width: width attribute not set description: no alt description found |
|
http://www.eisai.com/common/images/footer/to-top.png height: height attribute not set width: width attribute not set description: back to top |
|
http://www.eisai.com/common/images/logo_hhc.svg height: height attribute not set width: width attribute not set description: hhc human health care |
|
http://www.eisai.com/common/images/x-icon.svg height: height attribute not set width: width attribute not set description: x |
|
http://www.eisai.com/common/images/facebook-icon.svg height: height attribute not set width: width attribute not set description: facebook |
|
http://www.eisai.com/common/images/linkedin-icon.svg height: height attribute not set width: width attribute not set description: linkedin |
How are images contributing to your SEO site-wise ? Your leading content tool has the awnsers!